Trial Profile
A Phase I/II Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 10 Feb 2023
Price :
$35
*
At a glance
- Drugs Dabocemagene autoficel (Primary)
- Indications Epidermolysis bullosa dystrophica
- Focus Adverse reactions
- Sponsors Castle Creek Pharmaceuticals
- 06 Feb 2023 Status changed from active, no longer recruiting to discontinued.
- 25 Mar 2020 According to a Castle Creek Pharmaceuticals media release, results of this trial were presented at the inaugural World Congress on Epidermolysis Bullosa held in London during January of 2020.
- 25 Mar 2020 Results presented in a Castle Creek Pharmaceuticals media release.